The reduction in price target by HC Wainwright & Co. could lead to a negative short-term sentiment among investors, as it suggests a lower expected future stock price for Anavex Life Sciences. However, the maintenance of a Buy rating indicates the analyst's continued positive outlook on the company's fundamentals, which may mitigate some negative impact.